Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Yale Diabetes Research Center Molecular Genetics Core Resource Report Resource Website |
Yale Diabetes Research Center Molecular Genetics Core (RRID:SCR_015145) | access service resource, core facility, resource, service resource | Core facility which provides genetically modified mice and rodents, mainly transgenic and knockout mice and rodents in the NOD system. It also provides transgenic mice in F2 (usually B6/C3H) and rats on Sprague-Dawley, and chimeric mice using the 129 strain ES cells. It also provides training and management | genetically modified mice, genetically modified rodents, transgenic mice, knockout mice |
is listed by: NIDDK Information Network (dkNET) has parent organization: Yale University; Connecticut; USA has parent organization: Yale Diabetes Research Center is organization facet of: Yale Diabetes Research Center |
Diabetes | NIDDK P30DK045735 | Available to Yale Diabetes Research Center members | SCR_015145 | SciCrunch Registry | 2026-11-14 11:30:09 | 0 | ||||||||
|
Sparse Inverse Covariance Estimation for Ecological Association Inference Resource Report Resource Website 10+ mentions |
Sparse Inverse Covariance Estimation for Ecological Association Inference (RRID:SCR_022646) | SPIEC-EASI | software resource, software toolkit | Software R package estimates inverse covariance matrix from sequencing data.Statistical method for inference of microbial ecological networks from amplicon sequencing datasets. | inverse covariance matrix estimation, sequencing data, microbial ecological networks inference, amplicon sequencing datasets microbial ecological networks, | NIAID T32AI007180; NIDDK R01 DK103358; NIGMS RO1 GM63270; Simons Foundation |
PMID:25950956 | Free, Available for download, Freely available | SCR_022646 | SciCrunch Registry | SParse InversE Covariance Estimation for Ecological Association Inference | 2026-11-14 11:29:16 | 12 | |||||||
|
Teddy study IA prediction Resource Report Resource Website 1+ mentions |
Teddy study IA prediction (RRID:SCR_023303) | software resource, software toolkit | Software package to impute gene expression for all participants, whether they have partially or completely missing gene expression. | impute gene expression, gene expression, gene expression prediction | is related to: TEDDY | NIDDK U24DK097771 | DOI:10.1093/bib/bbac537 | Free, Available for download, Freely available | SCR_023303 | SciCrunch Registry | 2026-11-14 11:29:18 | 1 | ||||||||
|
Type 1 Diabetes - Rapid Access to Intervention Development Resource Report Resource Website |
Type 1 Diabetes - Rapid Access to Intervention Development (RRID:SCR_000203) | T1D-RAID | resource, service resource | NOTE: The T1D-RAID program is not currently accepting applications. Cooperative program that makes available, on a competitive basis, NCI resources for the pre-clinical development of drugs, natural products, and biologics to facilitate translation to the clinic of novel, scientifically meritorious therapeutic interventions for type 1 diabetes and its complications. A partial listing of those services includes: high-throughput screening, studies in animal models, formulation, pharmacology and toxicology studies, and bulk substances acquisition. Requests to T1D-RAID are brief (20 pages or less), and should clearly outline the resources required to ready the proposed therapeutic agent for clinical trials. T1D-RAID should enable entry into the clinic of promising molecules that are not otherwise likely to receive an adequate and timely clinical test. T1D-RAID is designed to accomplish the tasks that are rate-limiting in bringing discoveries from the laboratory to the clinic. Once a project has been approved, NIDDKstaff interact directly with the Principal Investigator (PI). NCI contractors perform the T1D-RAID-approved tasks under the direction of NIDDKand NCI staff. The required tasks will vary from project to project. In some cases T1D-RAID will support only one or two key missing steps necessary to bring a compound to the clinic; in other cases it may be necessary to supply the entire portfolio of development requirements needed to file an IND. Examples of tasks that can be supported by T1D-RAID include, but are not limited to: * Definition or optimization of dose and schedule for in vivo activity * Development of pharmacology assays * Conduct of pharmacology studies with a pre-determined assay * Acquisition of bulk substance (GMP and non-GMP) * Scale-up production from lab-scale to clinical-trials lot scale * Development of suitable formulations * Development of analytical methods for bulk substances * Production of dosage forms * Stability assurance of dosage forms * Range-finding initial toxicology * IND-directed toxicology, with correlative pharmacology and histopathology * Planning of clinical trials * Regulatory affairs, so that FDA requirements are likely to be satisfied by participating investigators seeking to test new molecular entities in the clinic * IND filing advice The output of T1D-RAID activities will be both products and information that will be made fully available to the originating investigator for support of an IND application and clinical trials. T1D-RAID does not sponsor clinical trials. | therapeutic, drug, drug development, pharmacogenomics |
is listed by: NIDDK Information Network (dkNET) is related to: Type 1 Diabetes Preclinical Testing Program has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Diabetes | NCI ; NIDDK |
nlx_152742 | SCR_000203 | SciCrunch Registry | Type 1 Diabetes - Rapid Access to Intervention Development (T1D-RAID) | 2026-11-14 11:29:23 | 0 | ||||||
|
Vanderbilt Diabetes Research and Training Center Islet Procurement and Analysis Core Resource Report Resource Website |
Vanderbilt Diabetes Research and Training Center Islet Procurement and Analysis Core (RRID:SCR_000896) | VU IPA Core | access service resource, core facility, resource, service resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on August 13,2025.Core facility that provides access to isolated pancreatic islets from normal and diabetic models and performs islet functional analysis. The IPA Core also provides solutions for high-resolution whole slide imaging and access to image analysis tools for quantitative assessment of pancreatic islet morphology. | diabetes, pancreas, islet functional analysis, pancreatic islet morphology |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: Vanderbilt University; Tennessee; USA has parent organization: Vanderbilt Diabetes Research and Training Center is organization facet of: Vanderbilt Diabetes Research and Training Center |
Diabetes | NIDDK DK020593 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_156666 | http://eagle-i.ea.vanderbilt.edu/i/00000139-b6a3-c300-b341-4bb480000000 | SCR_000896 | SciCrunch Registry | 2026-11-14 11:29:25 | 0 | |||||
|
Penn Diabetes Research Center Mouse Phenotyping Physiology and Metabolism Core Resource Report Resource Website |
Penn Diabetes Research Center Mouse Phenotyping Physiology and Metabolism Core (RRID:SCR_000888) | access service resource, core facility, resource, service resource | Core which provides researchers with resources for performing metabolic studies in mice. It also provides services, innovative techniques, and helpful consultation to both experienced and novice investigators with regards to metabolic questions. | mouse phenotyping, metabolism research |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: University of Pennsylvania; Philadelphia; USA has parent organization: Penn Diabetes Research Center is organization facet of: Penn Diabetes Research Center |
Diabetes | NIDDK P30DK19525 | Available to the DRC community, Acknowledgement requested | nlx_156493 | SCR_000888 | SciCrunch Registry | 2026-11-14 11:29:25 | 0 | |||||||
|
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease Resource Report Resource Website 1+ mentions |
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (RRID:SCR_000690) | CRISP | clinical trial, resource | A five-year prospective cohort study following 240 patients who have autosomal-dominant polycystic kidney disease (PKD) to determine whether changes in anatomic characteristics of their kidneys as measured by magnetic resonance imaging will be useful in providing surrogate measures for disease progression. CRISP's overall goal is to develop methods that would facilitate shortening the observation period necessary to determine efficacy of treatment interventions in PKD patients. Specific goals of this study are to: * Quantify cyst growth and ascertain severity of renal parenchymal involvement by sequential measurement of total kidney volume and the ratio of intact parenchyma to renal parenchyma occupied by cysts over time * Establish useful clinical correlations of imaging data with other markers of disease progression * Identify and test other potential markers or indices of disease progression, for example, assessment of loss of heterozygosity of renal cells shed in the urine, or other markers, in cohorts of patients with PKD * Gain information about the cost-effectiveness, patient acceptability, and advantages and disadvantages of different imaging techniques used serially in patients with PKD. Some experience has been gained in establishing that repeat imaging of the same PKD patient, using these techniques, yields reproducible estimates of kidney size and the proportion of renal parenchyma occupied by cysts. MRI may also have the advantage of permitting simultaneous estimation of GFR. Ultrasound has the advantage of being more cost-effective and perhaps more acceptable to patients for repetitive studies, but the measurements may be less accurate and reproducible. Nonetheless, there is very limited experience in applying these techniques to follow progression of the renal disease. Development of improved, reproducible imaging methods that assess cyst growth and provide markers of disease progression could markedly improve the feasibility of clinical trials. Participating clinical centers are Emory University, the Mayo Clinic, University of Kansas, and the University of Alabama at Birmingham. The data coordinating and imaging analysis center is at Washington University. (PI has since moved to University of Pittsburgh) The study found that kidney enlargement resulting from the expansion of cysts is continuous, quantifiable, and associated with the decline of renal function. Cystic expansion occurs at a consistent rate per individual, although it is heterogeneous in the population, and that larger kidneys are associated with more rapid decrease in renal function. These anatomic characteristics of patient kidneys may provide useful surrogate measures for disease progression, and hence enhance the development of targeted therapies for autosomal dominant PKD. CRISP III is a five-year prospective cohort study to follow ~170 remaining autosomal dominant polycystic kidney disease (ADPKD) patients who were part of the original CRISP cohort study. CRISP III will verify and extend the preliminary observations of CRISP to determine the extent to which quantitative (kidney volume and blood flow, and hepatic and kidney cyst volume) or qualitative (cyst distribution and character) structural parameters predict renal insufficiency and develop and test new metrics to quantify and monitor disease progression. Urine metabolites and the genome will be correlated with the progression of disease to look for new, predictive disease biomarkers. This information from CRISP III will help determine if the kidney enlargement, blood flow, cyst distribution, or urine metabolites can function as an informative surrogate measure for disease progression. | mri, kidney volume, cyst volume, kidney, renal function, disease progression, measure, blood flow, hepatic cyst volume, kidney cyst volume, renal insufficiency, urine metabolite, surrogate measure, clinical, intervention |
is listed by: NIDDK Information Network (dkNET) has parent organization: University of Pittsburgh; Pennsylvania; USA |
Polycystic kidney disease, Autosomal dominant polycystic kidney disease | NIDDK 5U01DK056961 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152795 | SCR_000690 | SciCrunch Registry | Consortium of Radiologic Imaging Study of PKD | 2026-11-14 11:29:24 | 3 | |||||
|
Medical Therapy of Prostatic Symptoms Resource Report Resource Website 1+ mentions |
Medical Therapy of Prostatic Symptoms (RRID:SCR_001556) | MTOPS | clinical trial, resource | Multi-center double-masked, placebo-controlled randomized clinical trial designed to evaluate the long-term efficacy of finasteride, or doxazosin, or the combination of both, in delaying or preventing the clinical progression of symptomatic benign prostatic hyperplasia (BPH). MTOPS was the largest and longest study to test whether drug therapy can prevent or delay the noncancerous growth of the prostate. A unique feature of MTOPS that has not been done in prior studies of pharmacotherapy of BPH is the biopsy substudy. A total of 1,082 volunteers from the 2,931 participants randomized during the full-scale phase are currently participating in this substudy. Biopsies of the prostate will be obtained on these volunteers at predetermined times during the course of the trial to evaluate the status of the prostate at key event times. The purpose of the substudy was to provide additional information regarding the histopathobiology of BPH and to test existing biomarkers for their prognostic ability regarding response to drug therapy. | male, adult human, prostate, placebo, finasteride, doxazosin, drug, treatment, prostate biopsy, tissue, prostate tissue, intervention, biomaterial supply resource, biomarker, serum |
is listed by: One Mind Biospecimen Bank Listing is listed by: ClinicalTrials.gov is affiliated with: MTOPS Prostate Samples Analysis Consortium has parent organization: George Washington University; Washington D.C.; USA |
Benign prostatic hyperplasia | NIDDK U01DK46472 | Free, Freely available | nlx_152863 | SCR_001556 | SciCrunch Registry | Medical Therapy of Prostatic Symptoms (MTOPS) | 2026-11-14 11:29:27 | 1 | |||||
|
National Diabetes Education Program Resource Report Resource Website 10+ mentions |
National Diabetes Education Program (RRID:SCR_001477) | NDEP | resource, training resource | Federal government public education program that promotes diabetes prevention and control. They aim to reduce the morbidity and mortality associated with diabetes and its complications. The NDEP is jointly sponsored by the National Institutes of Health and the Centers for Disease Control and Prevention and over 200 partner organizations. Target audiences include people with diabetes and those at risk, including the racial and ethnic populations disproportionately affected by the disease, health care providers and payers and purchasers of health care. | treatment, outcome, diabetes, diagnosis, prevention, blood glucose level, complication, education, disease-related portal |
is listed by: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Type 2 diabetes, Diabetes | NIDDK N02DK72927-8-0-1 | Free, Freely available | nlx_152708 | SCR_001477 | SciCrunch Registry | 2026-11-14 11:29:26 | 38 | ||||||
|
Diabetes Prevention Program Outcomes Study Resource Report Resource Website |
Diabetes Prevention Program Outcomes Study (RRID:SCR_001502) | DPPOS | clinical trial, data or information resource, database, resource | Observational clinical trial studying the long term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the Diabetes Prevention Program (DPP). The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%. The DPPOS is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest IGT population ever studied. Clinically important research questions remain that focus on 1)durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding CVD, CVD risk factors and atherosclerosis and microvascular disease, 3)close examination of these topics in men vs women and in minority populations. More than 87% of the original surviving DPP cohort has joined DPPOS as of December, 2007 and, to date, after 5 years of DPPOS and 10 years of combined DPP/DPPOS, 93% of the DPPOS cohort continue to attend annual follow-up visits. Interim analyses performed after 5 years of DPPOS have demonstrated a durable effect of diabetes prevention associated with the lifestyle and metformin interventions with 34 and 19% reductions in diabetes incidence, respectively, compared with the placebo group. Interim analyses also reveal significant reductions from baseline in CVD risk factors in the lifestyle intervention group, but with decreased utilization of glucose-lowering and lipid-lowering medications. Analyses of the participants in the placebo group who have developed diabetes during DPP/DPPOS, compared with those who have remained non-diabetic, reveal an increased frequency of retinopathy and microalbuminuria. The current, updated protocol describes the DPPOS including the revisions incorporated to complete the second five-years of the study. DPPOS participants have blood samples stored at the time of each annual visit. Specimens are stored at the study CBL until after the primary study outcomes are reported. DNA samples were previously collected and are stored at the NIDDKsample repository for DPP participants. | adult human, late adult human, male, female, caucasian, african-american, hispanic american, asian, pacific islander-american, american indian, metformin, microangiopathic, neuropathic, outcome, placebo, diabetic retinopathy, diabetic neuropathy, albuminuria, renal failure, macrovascular disease, cardiovascular disease, atherosclerosis, risk factor, amputation, hospitalization, physical activity, nutrition, body mass, obesity, dietary behavior, exercise behavior, physical functioning, quality of life, health care cost, cognitive performance, urinary incontinence, observational, microvascular disease, blood, dna |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository has parent organization: George Washington University; Washington D.C.; USA |
Type 2 diabetes, Diabetes | NIDDK U01DK048514; NIDDK U01DK048437; NIDDK U01DK048413; NIDDK U01DK048406; NIDDK U01DK048380; NIDDK U01DK048397 |
Free, Freely available | nlx_152800 | SCR_001502 | SciCrunch Registry | 2026-11-14 11:29:26 | 0 | ||||||
|
Look AHEAD Resource Report Resource Website 10+ mentions |
Look AHEAD (RRID:SCR_001490) | Look AHEAD | clinical trial, resource | 16-center, randomized clinical trial investigating the long-term health consequences of an intensive lifestyle intervention program designed to achieve and maintain weight loss by decreased caloric intake and increased physical activity in overweight volunteers with type 2 diabetes. The Look AHEAD cohort comprises approximately 5,000 overweight or obese participants with type 2 diabetes, aged 45-76. Participants were randomized to one of two interventions: an intensive lifestyle intervention designed to produce and sustain weight loss over the long term or a diabetes support and education arm. Participants will be followed for a total of 11 to 13.5 years from randomization. The primary hypothesis is that the incidence rate of the first post-randomization occurrence of a composite outcome, which includes * cardiovascular death (including fatal myocardial infarction and stroke), * non-fatal myocardial infarction, * hospitalized angina, and * non-fatal stroke, over a planned follow-up period of up to 13.5 years will be reduced among participants assigned to the Lifestyle Intervention compared to those assigned to the control condition, Diabetes Support and Education. Look AHEAD will also test for reductions in the incidence of three secondary composite outcomes and examine the effect of the intervention on cardiovascular disease risk factors, diabetes control and complications, general health, and quality of life, and psychological outcomes. The cost and cost-effectiveness of the Lifestyle Intervention relative to Diabetes Support and Education will be assessed. The Look AHEAD intensive lifestyle intervention ended September, 2012. Participants continue to be followed to determine the long-term effects of the intervention on health outcomes. | weight loss, caloric intake, physical activity, health outcome, long-term effect, longitudinal, intervention, late adult human, middle adult human, cardiovascular disease, risk factor, diabetes control, diabetes complication, health, quality of life, psychological outcome, clinical |
is listed by: NIDDK Information Network (dkNET) has parent organization: Wake Forest University; North Carolina; USA |
Type 2 diabetes, Overweight, Control | NIDDK U01DK057136 | Restricted | nlx_152745 | https://www.lookaheadtrial.org/public/home.cfm | SCR_001490 | SciCrunch Registry | Action for Health in Diabetes, Look AHEAD - Action for Health in Diabetes | 2026-11-14 11:29:26 | 48 | ||||
|
Frequent Hemodialysis Network Daily Trial Resource Report Resource Website 1+ mentions |
Frequent Hemodialysis Network Daily Trial (RRID:SCR_001527) | FHN Daily Trial | clinical trial, resource | Randomized controlled clinical trial to understand how increasing hemodialysis to six times a week from the standard of three times a week may result in improved heart health. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 1 year. Subjects will be randomized to either conventional hemodialyis Daily HD delivered for at least 2.5 hours (typically 3 to 4 hours), 3 days per week, or to more frequent hemodialysis delivered for 1.5 - 2.75 hours, 6 days per week. The study has two co-primary outcomes: 1) a composite of mortality with the change over 12 months in left ventricular mass by magnetic resonance imaging, and 2) a composite of mortality with the change over 12 months in the SF-36 RAND physical health composite (PHC) quality of life scale. In addition, main secondary outcomes have been designated for each of seven outcome domains: 1) cardiovascular structure and function (change in LV mass), 2) health-related quality of life/physical function (change in the PHC), 3) depression/burden of illness (change in Beck Depression Inventory), 4) nutrition (change in serum albumin), 5) cognitive function (change in the Trail Making Test B), 6) mineral metabolism (change in average predialysis serum phosphorus), and 7) clinical events (rate of non-access hospitalization or death). Hypertension and anemia are also main outcome domains, but without designation of single first priority outcomes. | hemodialysis, cardiovascular, kidney, heart |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is related to: Frequent Hemodialysis Network Nocturnal Trial has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Hemodialysis, End Stage Renal Disease | NIDDK | PMID:21091062 PMID:17164834 PMID:17699439 |
Free, Freely available | nlx_152828 | https://www.niddk.nih.gov/news/for-reporters/frequent-hemodialysis-network-daily-trial/Pages/default.aspx | SCR_001527 | SciCrunch Registry | Frequent Hemodialysis Network (FHN) Daily Trial | 2026-11-14 11:29:26 | 1 | |||
|
Viral Resistance to Antiviral Therapy of Chronic Hepatitis C Resource Report Resource Website |
Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (RRID:SCR_001553) | Virahep-C | clinical trial, resource | Study designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for differences in response, regardless of race, will be studied. All patients were treated with combination therapy of pegylated interferon and ribavirin for 48 weeks, and were followed for an additional 48 week safter cessation of therapy. 400 patients, half African-American and half Caucasian American, from 8 clinical centers with the goals of establishing rates of response to optimal current therapy in the two ethnic groups, identify factors predictive of response, establish patterns of viral kinetics in response to antiviral therapy, and test hypotheses concerning viral and host factors determining response to therapy. Four ancillary studies designed to elucidate biological and virological basis for non-response are also included in Virahep-C. Additionally, the study has central facilitates for pathology, the virological testing laboratory and a serum/tissue repository. | african-american, pegylated interferon, drug, ribavirin, caucasian-american, chronic hepatitis c genotype 1, biomaterial supply resource, efficacy, treatment, adult human, male, female, interferon, resistance, antiviral therapy, serum, tissue |
is listed by: One Mind Biospecimen Bank Listing is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: University of Pittsburgh; Pennsylvania; USA |
Chronic hepatitis C, Hepatitis C virus | NIDDK U01DK60329 | Free, Freely available | nlx_152861 | http://www.edc.gsph.pitt.edu/virahepc/, http://www.virahepc.org/ | SCR_001553 | SciCrunch Registry | Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C), Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C | 2026-11-14 11:29:27 | 0 | ||||
|
TINSAL-T2D Resource Report Resource Website 1+ mentions |
TINSAL-T2D (RRID:SCR_001546) | TINSAL-T2D, TINSAL-T2D-II | clinical trial, resource | Nationwide, randomized, double blind, multi-center research study to determine whether the drug salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type 2 diabetes. The study is conducted in two stages. The primary objective of the first stage is to select a dose of salsalate that is both well-tolerated and demonstrates a trend toward improvement in glycemic control. The primary objective of Stage 2 of the study is to evaluate the effects of salsalate on blood sugar control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes (T2D); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and cardiac risk. | salsalate, drug, intervention, treatment, hba1c, inflammation, obesity, metabolic syndrome, adult human, male, female, non-steroidal anti-inflammatory drug, diabetes management, placebo, glycemic control |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) has parent organization: Joslin Diabetes Center |
Type 2 diabetes, Inflammation, Metabolic syndrome, Cardiac disease, Obesity | NIDDK 5R01DK095327 | PMID:20231565 PMID:17959861 |
Free, Freely available | nlx_152855 | https://clinicaltrials.gov/ct2/show/NCT00392678 | http://www.tinsal-t2d.org/ | SCR_001546 | SciCrunch Registry | Targeting Inflammation Using Salsalate for Type 2 Diabetes-stage II, Targeting INflammation using SALsalate for Type 2 Diabetes | 2026-11-14 11:29:27 | 1 | ||
|
Study of Nutrition in Acute Pancreatitis Resource Report Resource Website |
Study of Nutrition in Acute Pancreatitis (RRID:SCR_001544) | SNAP | clinical trial, resource | Randomized multi-center clinical trial designed to test whether duodenojejunal (DJ) feeding is more effective than nasogastric (NG) feeding in providing enteral nutrition to patients with severe acute pancreatitis. SNAP will enroll participants with severe acute pancreatitis admitted to the intensive care unit at eight clinical centers. Upon enrollment, participants are assigned to NG or DJ feeding and managed for up to 28 days or until weaned on to solid food. Follow-up continues until participants are discharged from the hospital or for a maximum of 60 days. Outcomes relate to feeding tolerance and failure, nutritional status, risk for life-threatening pancreatic/systemic complications, and hospital mortality. | duodenojejunal feeding, naso gastric feeding, enteral nutrition, feeding tolerance, outcome, acute pancreatitis, distal jejunal feeding, intervention, nutrition, treatment, adult human, male, female, pancreas |
is listed by: ClinicalTrials.gov is listed by: NIDDK Research Resources is listed by: NIDDK Information Network (dkNET) has parent organization: University of Pittsburgh; Pennsylvania; USA |
Pancreatitis | NIDDK | Free, Freely available | nlx_152854 | SCR_001544 | SciCrunch Registry | 2026-11-14 11:29:27 | 0 | ||||||
|
Peginterferon and Ribavirin for Pediatric Patients with Chronic Hepatitis C Resource Report Resource Website |
Peginterferon and Ribavirin for Pediatric Patients with Chronic Hepatitis C (RRID:SCR_006787) | PEDS-C | clinical trial, resource | Multi-center, randomized controlled trial that studied peginterferon therapy, with or without ribavirin, in children with chronic hepatitis C. Approximately 120 children were randomly assigned to receive peginterferon alfa-2a alone or peginterferon with ribavirin for 48 weeks. Samples of blood, genomic DNA, and liver tissue are stored in the NIDDKrepositories. A long-term follow up study of the clinical trial participants is underway. | child, young human, peginterferon alfa-2a, ribavirin, drug, male, female, adolescent, pediatric |
is listed by: One Mind Biospecimen Bank Listing is listed by: NIDDK Research Resources is listed by: NIDDK Information Network (dkNET) is related to: NIDDK Central Repository has parent organization: ClinicalTrials.gov |
Chronic hepatitis C viral infection, Hepatitis C virus | NIDDK | PMID:18042575 | nlx_152846 | http://www.pedsc.org | SCR_006787 | SciCrunch Registry | Pegylated Interferon +/- Ribavirin for Children With Hepatitis C, Peginterferon and Ribavirin for Pediatric Patients with Chronic Hepatitis C (Peds-C) | 2026-11-14 11:29:32 | 0 | ||||
|
Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction Resource Report Resource Website |
Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (RRID:SCR_006897) | EPISOD | clinical trial, resource | A prospective, double-blind, randomized, sham-controlled, multi-center clinical trial that enrolls subjects who have received a prior cholecystectomy and are diagnosed with the clinical syndrome of Sphincter of Oddi Dysfunction III (SOD III) as defined by the Rome III criteria. The goal of the study is to asses the value of endoscopic sphincterotomy as a treatment for adult subjects categorized as SOD III suffering from pain after cholecystectomy and to define the role of manometry in treating these patients. | clinical, treatment, intervention, sphincterotomy, pancreatic, pancreas, pancreatitis, biliary, adult human, male, female, manometry |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources |
Cholecystectomy, Sphincter of Oddi Dysfunction | NIDDK | nlx_152824 | http://www.episod.org/ | SCR_006897 | SciCrunch Registry | Evaluating Predictors & Interventions in Sphincter of Oddi Dysfunction, Evaluating Predictors & Interventions in Sphincter of Oddi Dysfunction (EPISOD) | 2026-11-14 11:29:33 | 0 | |||||
|
Complementary and Alternative Medicine for Urological Symptoms Resource Report Resource Website |
Complementary and Alternative Medicine for Urological Symptoms (RRID:SCR_007131) | CAMUS | clinical trial, resource | Randomized, multicenter, double blind, placebo controlled clinical trial of phytotherapy for benign prostate symptoms among men. The CAMUS trial will test Saw palmetto in about 369 men. Men who decide to be part of the CAMUS trial will be given one out of two possible treatments at random. One out of every two men would get an inactive placebo treatment. One out of every two men would get Saw palmetto pills. This kind of scientific study is the best way to find out if the plant extracts really work to prevent men with benign prostatic hyperplasia (BPH) from getting worse. During the study, men will not know which of the two treatments they are assigned to. They will be followed very closely by a study team every 12 weeks to see how they are doing. Men in the CAMUS trial will be studied over 72 weeks. Ten clinical centers will participate in the trial. They are located at: Columbia University, NY, NY; New York University, NY, NY; University of Texas Southwestern Medical Center, Dallas, Texas; University of Colorado, Denver, CO; Washington University, St. Louis, MO; Yale University, New Haven, CT; Queens University, Hamilton, Ontario, Canada; Northwestern University, Chicago, IL; University of Maryland, Baltimore, MD; University of California at San Francisco, San Francisco, CA. | phytotherapy, prostate, benign, treatment, male, adult human, saw palmetto, placebo, herbal therapy, middle adult human, late adult human, urology |
is listed by: ClinicalTrials.gov is related to: NIDDK Information Network (dkNET) has parent organization: University of Alabama at Birmingham; Alabama; USA |
Benign prostatic hyperplasia | NCCAM ; NIDDK ; Office of Dietary Supplements ; NIDDK U01DK63795; NIDDK U01DK63797; NIDDK U01DK63825; NIDDK U01DK63835; NIDDK U01DK63866; NIDDK U01DK63833; NIDDK U01DK63862; NIDDK U01DK63840; NIDDK U01DK63883; NIDDK U01DK63831; NIDDK U01DK63778; NIDDK U01DK63788 |
PMID:21954478 PMID:21741692 PMID:21497839 |
nlx_152791 | http://www.camus.uab.edu/camus/html/index.htm |
SCR_007131 | SciCrunch Registry | Complementary and Alternative Medicine for Urological Symptoms Clinical Trial, Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Clinical Trial, Complementary and Alternative Medicine for Urological Symptoms (CAMUS) | 2026-11-14 11:29:33 | 0 | ||||
|
Focal Segmental Glomerulosclerosis in Children and Young Adults Interventional Study Resource Report Resource Website |
Focal Segmental Glomerulosclerosis in Children and Young Adults Interventional Study (RRID:SCR_007130) | FSGS in Children and Young Adults Interventional Study | clinical trial, resource | Network of collaborative research centers that tested the effects of treatment with cyclosporine to treatment with mycophenalate mofetil combined with oral pulse dexamethasone in children and young adults with focal segemental glomerulosclerosis. Efficacy was assessed in terms of induction of remission of proteinuria after 52 weeks of treatment and sustained remission after 26 weeks off treatment. The clinical sites were State University of New York, Stony Brook; Montefiore Medical Center; Seattle Children''''s Medical Center; Medical City Dallas Hospital; and the University of North Carolina. The Cleveland Clinic is the data-coordinating center, and NephCure will fund ancillary studies. | child, early adult, young human, proteinuria, kidney disease, intervention, prednisone, cyclosporine, mycophenalate mofetil, dexamethasone, cyclosporine-a, male, female |
is listed by: ClinicalTrials.gov is affiliated with: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Focal Segmental Glomerulosclerosis, Focal Segmental Glomerulosclerosis Nephrotic Syndrome | NIDDK | nlx_152826 | http://www.fsgstrial.org | SCR_007130 | SciCrunch Registry | Focal Segmental Glomerulosclerosis Clinical Trial, Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT), Focal Segmental Glomerulosclerosis (FSGS) Clinical Trial, Focal Segmental Glomerulosclerosis (FSGS) in Children and Young Adults Interventional Study | 2026-11-14 11:29:33 | 0 | |||||
|
Minimally Invasive Surgical Therapies Treatment Consortium for Benign Prostatic Hyperplasia Resource Report Resource Website |
Minimally Invasive Surgical Therapies Treatment Consortium for Benign Prostatic Hyperplasia (RRID:SCR_007126) | MIST for BPH | clinical trial, resource | Randomized clinical trial to determine the efficacy and safety of three treatments for benign prostatic hyperplasia (BPH): transurethral needle ablation (TUNA), transurethral microwave therapy (TUMT), and medical therapy with alfuzosin and finasteride. The study has been terminated. (Inability to recruit required sample size.) | transurethral microwave thermotherapy, transurethral needle ablation, therapy, drug, finasteride, alfuzosin, treatment, clinical, intervention, male, middle adult human, late adult human, prostate |
is listed by: ClinicalTrials.gov is related to: NIDDK Information Network (dkNET) has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Benign Prostatic Hyperplasia | NIDDK | nlx_152844 | SCR_007126 | SciCrunch Registry | Minimally Invasive Surgical Therapies (MIST) Treatment Consortium for Benign Prostatic Hyperplasia (BPH), Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia | 2026-11-14 11:29:33 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the dkNET Resources search. From here you can search through a compilation of resources used by dkNET and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that dkNET has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on dkNET then you can log in from here to get additional features in dkNET such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into dkNET you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.